Citations

Clear

9383 citation(s) found for "Thomas, PS".

The Impact, Reach, and Community Involvement of #ContinuumCase (S39.006)
Albin, Casey, Doering, Amanda F., Pacific, Thomas, Siegler, James E. , Jones, Lyell K.

Mayo Clinic

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000205688 Get It

Education on Preventative Migraine Therapy Impacts Real-world Treatment Selection (P4-12.010)
Lucero, Katie , Finnegan, Thomas , Tepper, Stewart J. , Starling, Amaal J.

Mayo Clinic

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000205263 Get It

Conjugal Synucleinopathies: A Clinicopathologic Study (P7-3.014)
Halverson, Matthew , Chiu, Shannon , Shill, Holly A. , Driver‐Dunckley, Erika , Mehta, Shyamal H. , Caviness, John N., Belden, Christine M. , Long, Kathy E., Beach, Thomas G. , Adler, Charles H. , Zhang, Nan , Atri, Alireza , Serrano, Geidy E. , Shprecher, David , Sabbagh, Marwan Noel

Mayo Clinic

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000204916 Get It

Results from a Phase 2 Clinical Trial of Repeated Intrathecal Autologous Adipose-derived MSCs in ALS (S5.004)
Muzyka, Iryna , Madigan, Nicolas N. , Mester, Carly , Turner, Michelle, Thuro, L. M., Osgood, Thomas A., Madde, Pranathi, Deeds, Michael , Wiltshire, Timothy D. , Mandrekar, Jayawant N. , Windebank, Anthony J. , Staff, Nathan P. , Oskarsson, Björn , Figdore, Daniel J. , Turner, Michelle, Algeciras‐Schimnich, Alicia , Dietz, Allan B.

Mayo Clinic

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000204894 Get It

Neuropathological Profile of Cases with Mild Cognitive Impairment (S1.009)
Mehta, Shyamal H. , Shill, Holly A. , Driver‐Dunckley, Erika , Belden, Christine M. , Beach, Thomas G. , Ho, Andrew Fu Wah , Choudhury, Parichita , Adler, Charles H. , Shprecher, David , Serrano, Geidy E. , Atri, Alireza , Tremblay, Cécilia

Mayo Clinic

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000204810 Get It

Guidelines for Pathologic Diagnosis of Mesothelioma: 2023 Update of the Consensus Statement From the International Mesothelioma Interest Group
Husain, Aliya N. , Chapel, David B. , Attanoos, Richard , Beasley, Mary Beth , Butnor, Kelly J. , Đačić, Sanja , Hiroshima, Kenzo , Hung, Yin P. , Klebe, Sonja , Krausz, Thomas, Khoór, András , Litzky, Leslie A., Nabeshima, Kazuki , Roden, Anja C. , Roggli, Victor L., Schulte, Jefree J. , Sheaff, Michael , Walts, Ann E. , Colby, Thomas V. , Hung, Yin P , Brčić, Luka , Chirieac, Lucian R. , Churg, Andrew , Marchevsky, Alberto M. , Nicholson, Andrew G. , Pavlisko, Elizabeth N. , Sauter, Jennifer L. , Travis, William D. , Tsao, Ming‐Sound

Mayo Clinic

Archives of Pathology & Laboratory Medicine | April 8, 2024 | Volume: 148 | Issue: 11 | Pages: 1251-1271

10.5858/arpa.2023-0304-ra | PMID 38586983 Get It

Context.— Mesothelioma is an uncommon tumor that can be difficult to diagnose. Objective.— To provide updated, practical guidelines for the pathologic diagnosis of mesothelioma. Data Sources.— Pathologists involved in the International Mesothelioma Interest Group and others with expertise in mesothelioma contributed to this update. Reference material includes peer-reviewed publications and textbooks. Conclusions.— There was consensus opinion regarding guidelines for (1) histomorphologic diagnosis of mesothelial tumors, including distinction of epithelioid, biphasic, and sarcomatoid mesothelioma; recognition of morphologic variants and patterns; and recognition of common morphologic pitfalls; (2) molecular pathogenesis of mesothelioma; (3) application of immunohistochemical markers to establish mesothelial lineage and distinguish mesothelioma from common morphologic differentials; (4) application of ancillary studies to distinguish benign from malignant mesothelial proliferations, including BAP1 and MTAP immunostains; novel immunomarkers such as Merlin and p53; fluorescence in situ hybridization (FISH) for homozygous deletion of CDKN2A; and novel molecular assays; (5) practical recommendations for routine reporting of mesothelioma, including grading epithelioid mesothelioma and other prognostic parameters; (6) diagnosis of mesothelioma in situ; (7) cytologic diagnosis of mesothelioma, including use of immunostains and molecular assays; and (8) features of nonmalignant peritoneal mesothelial lesions.
Efficacy and safety of tranexamic acid in the management of chronic subdural hematoma: a systematic review and meta-analysis
Salim, Hamza , Adeeb, Nimer , Spellicy, Samantha , Abdelgadir, Jihad , Guthikonda, Bharat , Azar, Jehad , Salim, Hamza , Musmar, Basel , Orscelik, Atakan , Cuellar, Hugo , Jabbour, Pascal , Hasan, David

Mayo Clinic

Journal of Neurosurgery | April 5, 2024 | Volume: 141 | Issue: 4 | Pages: 945-954

10.3171/2024.1.jns232463 | PMID 38579356 Get It

OBJECTIVE Chronic subdural hematoma (CSDH) is a prevalent neurosurgical condition, particularly among the elderly. Various treatment options exist, but recurrence rates remain high. This systematic review and meta-analysis aims to assess the efficacy and safety of tranexamic acid (TXA) in the management of CSDH. METHODS The authors conducted a comprehensive literature search adhering to the 2020 PRISMA guidelines, involving three primary databases (Scopus, PubMed, and Web of Science) that were searched for articles compiled from inception until October 20, 2023. The primary outcome was recurrence of CSDH, and secondary outcomes included complications and SDH volume following TXA treatment. The mean difference and odds ratios with 95% confidence intervals were calculated using the random-effects model. RESULTS A total of 5 studies, involving 643 patients in the TXA group and 736 patients in the non-TXA group, met the inclusion criteria. The meta-analysis revealed that TXA use led to a significantly lower CSDH recurrence (OR 0.35, 95% CI 0.23–0.53; p < 0.01) without increasing complications (OR 1.84, 95% CI 0.43–7.95; p = 0.42). Additionally, TXA users had a significantly lower CSDH volume compared to the non-TXA group at 3-month follow-up (mean difference −4.56, 95% CI −8.76 to −0.36; p = 0.03). CONCLUSIONS The findings suggest that TXA might be a promising agent for reducing the risk of CSDH recurrence without elevating the risk of complications. However, these results should be interpreted cautiously due to the limited number of studies included and the methodological heterogeneity. Further large-scale randomized controlled trials are needed to confirm these findings.
CREST‐2 Commitment to Rigorous Assessment of Carotid Stenting for Primary Prevention of Stroke
Edwards, Lloyd J. , Roubin, Gary S., Brott, Thomas G. , Lal, Brajesh K. , Edwards, Lloyd J. , Meschia, James F.

Mayo Clinic

Stroke: Vascular and Interventional Neurology | April 5, 2024 | Volume: 4 | Issue: 3 | Pages: No page available

10.1161/svin.123.001227 | PMID 40630854 Get It

Background Rather than considering carotid stenting and endarterectomy to be rival procedures, they ought to be seen as complementary, with some patients more suited to one procedure over another. The respective patient populations best suited for optimal outcomes with stenting and endarterectomy differ substantially. Hence, the CREST‐2 (Carotid Revascularization, Endarterectomy Versus Stent Trial‐2) ( study was designed as 2 separate 2‐arm randomized trials run in parallel. One trial compares intensive medical management with and without stenting; the other, intensive medical management with and without endarterectomy. Each trial has a recruitment target of 1240 patients with ≥70% asymptomatic carotid stenosis, randomized 1:1 in each arm. To ensure patient safety and give stenting the best possible chance of demonstrating net benefits in stroke prevention, CREST‐2 adopted a rigorous procedure for evaluating, monitoring, and approving operators to enroll in the trial. The CREST‐2 Registry was established to allow for recent experience for applicant stent operators. Methods The CREST‐2 Registry is a prospective, multicenter, short‐term observational study of carotid stenting allowing use of multiple devices. Results The registry enrolled its first patient in September 2014, and as of October 2, 2023, a total of 9830 patients have been treated by 207 different stent operators from 103 different clinical centers. In this mixed cohort of asymptomatic (61.1% of the cohort) and symptomatic (38.9%) patients, the 30‐day stroke rate is 1.8% and the combined 30‐day stroke or death rate is 2.6%. At its peak in March 2016, the registry achieved an enrollment rate of 142 cases/month. As of October 20, 2023, a total of 104 patients remain to be enrolled in the CREST‐2 stenting trial. Conclusion The registry has facilitated assembly of a high‐performing team of stent operators for the CREST‐2 trial. With continued support of the many operators, we anticipate completing enrollment by the summer of 2024.
5-Year Follow-Up of a Physician Performance Feedback Report Intervention to Reduce Overuse and Excess Cost: A National Cohort Study
Walsh, Christi, Stasko, Thomas, Vidimos, Allison T. , Leshin, Barry, Billingsley, Elizabeth M. , Coldiron, Brett M., Bennett, Richard G. , Marks, Victor J., Otley, Clark C. , Rogers, Howard W., Goldman, Glenn D., Albertini, John G., Makary, Martin A. , Dun, Chen , Hicks, Caitlin W.

Mayo Clinic

Dermatologic Surgery | April 5, 2024 | Volume: 50 | Issue: 6 | Pages: 558-564

10.1097/dss.0000000000004165 | PMID 38578837 Get It

BACKGROUND Mohs micrographic surgery efficiently treats skin cancer through staged resection, but surgeons' varying resection rates may lead to higher medical costs. OBJECTIVE To evaluate the cost savings associated with a quality improvement. MATERIALS AND METHODS The authors conducted a retrospective cohort study using 100% Medicare fee-for-service claims data to identify the change of mean stages per case for head/neck (HN) and trunk/extremity (TE) lesions before and after the quality improvement intervention from 2016 to 2021. They evaluated surgeon-level change in mean stages per case between the intervention and control groups, as well as the cost savings to Medicare over the same time period. RESULTS A total of 2,014 surgeons performed Mohs procedures on HN lesions. Among outlier surgeons who were notified, 31 surgeons (94%) for HN and 24 surgeons (89%) for TE reduced their mean stages per case with a median reduction of 0.16 and 0.21 stages, respectively. Reductions were also observed among outlier surgeons who were not notified, reducing their mean stages per case by 0.1 and 0.15 stages, respectively. The associated total 5-year savings after the intervention was 92 million USD. CONCLUSION The implementation of this physician-led benchmarking model was associated with broad reductions of physician utilization and significant cost savings.
FAT1 weighted MRI: Diffusion meets anatomical imaging and application in thalamic surgery for tremor
Goedemans, Taco , Ferreira, Francisca , Wirth, Thomas , Weerd, Lonneke van der, Massey, Flavia V. , Krüger, Marie T., Milanese, Vanessa, Pakzad, Ashkan , Limousin, Patricia , Bot, Maarten , Schuurman, Rick , Foltynie, Thomas , Munckhof, Pepijn van den , Zrinzo, Ludvic , Akram, Harith

Mayo Clinic

Imaging Neuroscience | April 5, 2024 | Volume: 2 | Issue: No issue available | Pages: No page available

10.1162/imag_a_00139 | PMID 40800267 Get It

Abstract Patient-specific targeting of the Ventral intermediate nucleus (Vim) of the thalamus can be achieved with MR connectivity. Nevertheless, there are several drawbacks to using tractography-based targeting methods to visualise distinct thalamic nuclei (e.g., subjective region of interest selection, and thresholding of resulting tracts and clusters). Fractional anisotropy (FA) mapping, another product of diffusion MRI (dMRI), does not rely on tractography, and could thus be clinically more viable for discerning thalamic anatomy for stereotactic surgery. The aim of this study is to develop and present a hybrid, high-resolution, and high-fidelity imaging modality that combines contrast from FA maps as well as anatomical T1 sequences (FAT1 imaging); and to evaluate FAT1 based Vim-target definition. Imaging and outcome data of 35 consecutive refractory tremor patients who had undergone 43 connectivity guided deep brain stimulation (DBS) and/or radiofrequency thermocoagulation (RF-T) between 2013 and 2021 were included. First, the pre-operatively acquired dMRI and MPRAGE sequences were used to create FAT1 maps in retrospect. Then, an FAT1 based Vim-target was planned by an experienced functional neurosurgeon who was blinded for patient outcome. Finally, to investigate FAT1 based targeting, a post-hoc analysis was carried out of the degree of overlap between the newly created FAT1 based Vim-target, and the volume of tissue activation (VTA, in case of DBS) or lesion volume (in case of RF-T). This degree of overlap was compared between favourable and unfavourable outcome groups: outcomes were measured by experts blinded for imaging data at the last follow-up using a Clinical Global Impression-Improvement score (CGI-I), where a CGI-I score of 1-2 (i.e., FTMTRS improvement of ≥50%) was considered favourable. In 36 of the 43 (84%) performed surgeries (24 DBS and 19 RF-T), FAT1 based Vim-targeting was possible. For the group showing favourable outcome (71% of the patients at a median follow-up of 13 months), the mean amount of overlap between the FAT1 based Vim-target and the VTA or lesion was 42% (±13), versus 17% (±15) for patients with an unfavourable outcome (MD 25%, 95% CI 14–35, p &lt; 0.0001). Retrospective use of FAT1 based Vim-targeting as a tool to predict outcome had a sensitivity of 90%, specificity of 80%, positive predictive value of 90%, and negative predictive value of 80%. In conclusion, FAT1 imaging is a new, high-resolution, and high-fidelity modality that combines diffusion and anatomical MRI. It provides a fast and efficacious way of targeting the ventral intermediate nucleus of the thalamus. In this study, FAT1 based targeting was highly accurate in predicting outcomes after deep brain stimulation and radiofrequency thalamotomy.